The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Targeting Multiple Signaling Pathways in Cancer: The Rutin Therapeutic Approach
Open accessAbstract
Multiple dysregulated signaling pathways are implicated in the pathogenesis of cancer. The conventional therapies used in cancer prevention/treatment suffer from low efficacy, considerable toxicity, and high cost. Hence, the discovery and development of novel multi-targeted agents to attenuate the dysregulated signaling in cancer is of great importance. In recent decades, phytochemicals from dietary and medicinal plants have been successfully introduced as alternative anticancer agents due to their ability to modulate numerous oncogenic and oncosuppressive signaling pathways. Rutin (also known as rutoside, quercetin-3-O-rutinoside and sophorin) is an active plant-derived flavonoid that is widely distributed in various vegetables, fruits, and medicinal plants, including asparagus, buckwheat, apricots, apples, cherries, grapes, grapefruit, plums, oranges, and tea. Rutin has been shown to target various inflammatory, apoptotic, autophagic, and angiogenic signaling mediators, including nuclear factor-κB, tumor necrosis factor-α, interleukins, light chain 3/Beclin, B cell lymphoma 2 (Bcl-2), Bcl-2 associated X protein, caspases, and vascular endothelial growth factor. A comprehensive and critical analysis of the anticancer potential of rutin and associated molecular targets amongst various cancer types has not been performed previously. Accordingly, the purpose of this review is to present an up-to-date and critical evaluation of multiple cellular and molecular mechanisms through which the anticancer effects of rutin are known to be exerted. The current challenges and limitations as well as future directions of research are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Advances in flavonoid research since 1992
Harborne, J. B., & Williams, C. A. (2000) · Phytochemistry · doi:10.1016/s0031-9422(00)00235-1 · Cited by 3,956
Inflammation and cancer: triggers, mechanisms, and consequences
Greten, F. R., & Grivennikov, S. I. (2019) · Immunity · doi:10.1016/j.immuni.2019.06.025 · Cited by 3,806
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.66 · Cited by 3,079 · cited 1×
“TNBC represents poor prognosis and outcome due to the lack of ideal target options [99].”
BackgroundPan-cancer analysis of whole genomes
The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, Aaltonen, L. A., Abascal, F., Abeshouse, A., Aburatani, H., Adams, D. J., Agrawal, N., Ahn, K. S., Ahn, S.-M., Aikata, H., et al. (2020) · Nature · doi:10.1038/s41586-020-1969-6 · Cited by 3,064
Fridman, J. S., & Lowe, S. W. (2003) · Oncogene · doi:10.1038/sj.onc.1207116 · Cited by 1,401 · cited 1×
“Tumor suppressor p53 can regulate the intrinsic pathway of apoptosis through controlling the B cell lymphoma 2 (Bcl-2) proteins family [58].”
BackgroundHow does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression
Aubrey, B. J., Kelly, G. L., Janic, A., Herold, M. J., & Strasser, A. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.169 · Cited by 1,395
Crosstalk between apoptosis.; necrosis and autophagy
Nikoletopoulou, V., Markaki, M., Palikaras, K., & Tavernarakis, N. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.06.001 · Cited by 1,366 · cited 2×
“PARP inhibitors expedite ROS production, DNA damage, and programmed cell death [59].”
BackgroundERK and cell death: mechanisms of ERK-induced cell death--apoptosis, autophagy and senescence
Cagnol, S., & Chambard, J. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2009.07366.x · Cited by 1,290 · cited 1×
“Additionally, ERK participates in crosstalk between programmed cell death and autophagy [188].”
BackgroundThe Cell–Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression
Chen, J. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026104 · Cited by 1,222 · cited 1×
“P53 is a well-known tumor suppressor gene that participates in the induction of cell cycle arrest and apoptosis [158].”
BackgroundThe Roles of Autophagy in Cancer
Yun, C. W., & Lee, S. H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113466 · Cited by 965 · cited 1×
“Autophagy (programmed cell death type II) is an intracellular regulated process that plays a vital role in the maintenance of cellular homeostasis by eliminating malformed and unwanted proteins [66].”
BackgroundMeta-analyses of colorectal cancer risk factors
Johnson, C. M., Wei, C., Ensor, J. E., Smolenski, D. J., Amos, C. I., Levin, B., & Berry, D. A. (2013) · Cancer Causes & Control · doi:10.1007/s10552-013-0201-5 · Cited by 779
The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer
Affo, S., Yu, L.-X., & Schwabe, R. F. (2017) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100322 · Cited by 757 · cited 2×
“Approximately 90% of liver cancers are recognized as hepatocellular carcinomas (HCCs) and 10% are cholangiocarcinomas (CCAs) [200].”
BackgroundThe Dual Roles of NRF2 in Cancer
Menegon, S., Columbano, A., & Giordano, S. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.05.002 · Cited by 633 · cited 1×
“may act as an anti- or as a pro-tumorigenesis [52].”
BackgroundThe BCL-2 arbiters of apoptosis and their growing role as cancer targets
Adams, J. M., & Cory, S. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.161 · Cited by 530
Muhamad, N., Plengsuriyakarn, T., & Na-Bangchang, K. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s165210 · Cited by 410
pH ‐Sensitive stimulus‐responsive nanocarriers for targeted delivery of therapeutic agents
Karimi, M., Eslami, M., Sahandi‐Zangabad, P., Mirab, F., Farajisafiloo, N., Shafaei, Z., Ghosh, D., Bozorgomid, M., Dashkhaneh, F., & Hamblin, M. R. (2016) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1389 · Cited by 327
Internal stimuli-responsive nanocarriers for drug delivery: Design strategies and applications
Liu, M., Du, H., Zhang, W., & Zhai, G. (2017) · Materials Science and Engineering: C · doi:10.1016/j.msec.2016.11.030 · Cited by 235
Expression and activity of potassium ion channels in human prostate cancer
Abdul, M., & Hoosein, N. (2002) · Cancer Letters · doi:10.1016/s0304-3835(02)00348-8 · Cited by 145
Stimuli-responsive chitosan-based nanocarriers for cancer therapy
Fathi, M., Sahandi Zangabad, P., Majidi, S., Barar, J., Erfan-Niya, H., & Omidi, Y. (2017) · BioImpacts · doi:10.15171/bi.2017.32 · Cited by 87
Cited by
Plant-Derived Anticancer Compounds as New Perspectives in Drug Discovery and Alternative Therapy
Dehelean, C. A., Marcovici, I., Soica, C., Mioc, M., Coricovac, D., Iurciuc, S., Cretu, O. M., & Pinzaru, I. (2021) · Molecules · doi:10.3390/molecules26041109 · Cited by 502
Diosmetin Exerts Synergistic Effects in Combination with 5-Fluorouracil in Colorectal Cancer Cells
Kamran, S., Sinniah, A., Chik, Z., & Alshawsh, M. A. (2022) · Biomedicines · doi:10.3390/biomedicines10030531 · Cited by 57
Metadata
- Authors
- Nouri, Z., Fakhri, S., Nouri, K., Wallace, C. E., Farzaei, M. H., & Bishayee, A.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2020-08-14
- Volume
- 12
- Issue
- 8
- Pages
- 2276
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3049079726
- Cited by
- 236
- References
- 19
- FWCI
- 13.15
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.